Skip to content

INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID‐19 (INHALE‐HEP): Protocol and Statistical Analysis Plan for an investigator‐initiated international meta‐trial of randomised studies

Research output: Contribution to journalArticlepeer-review

  • Frank M. P. Haren
  • Alice Richardson
  • Hwan‐Jin Yoon
  • Antonio Artigas
  • John G. Laffey
  • Barry Dixon
  • Roger Smith
  • Alicia B. Vilaseca
  • Ruben A. Barbera
  • Tarek I. Ismail
  • Rabab S. Mahrous
  • Mohamed Badr
  • Gilberto Denucci
  • Carlos Sverdloff
  • Lex M. Loon
  • Marta Camprubi‐Rimblas
  • David W. Cosgrave
  • Thomas L. Smoot
  • Sabrina Staas
  • Khine Sann
  • Caitlin Sas
  • Anusha Belani
  • Christopher Hillman
  • Mary Carroll
  • Tom Wilkinson
  • Miles Carroll
  • Dave Singh
  • Clive Page
Introduction: Inhaled nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale that warrants urgent investigation of its therapeutic potential in patients with COVID‐19. UFH has antiviral effects and prevents the SARS‐CoV‐2 virus’ entry into mammalian cells. In addition, UFH has significant anti‐inflammatory and anti‐coagulant properties, which limit progression of lung injury and vascular pulmonary thrombosis.

Methods and intervention: The INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID‐19 (INHALE‐HEP) meta‐trial is a prospective individual patient data analysis of on‐going randomised controlled trials and early phase studies. Individual studies are being conducted in multiple countries. Participating studies randomise adult patients admitted to the hospital with confirmed SARS‐CoV‐2 infection, who do not require immediate mechanical ventilation, to inhaled nebulised UFH or standard care. All studies collect a minimum core dataset. The primary outcome for the meta‐trial is intubation (or death, for patients who died before intubation) at day 28. The secondary outcomes are oxygenation, clinical worsening and mortality, assessed in time‐to‐event analyses. Individual studies may have additional outcomes.

Analysis: We use a Bayesian approach to monitoring, followed by analysing individual patient data, outcomes and adverse events. All analyses will follow the intention‐to‐treat principle, considering all participants in the treatment group to which they were assigned, except for cases lost to follow‐up or withdrawn.

Trial registration, ethics and dissemination: The meta‐trial is registered at ClinicalTrials.gov ID NCT04635241. Each contributing study is individually registered and has received approval of the relevant ethics committee or institutional review board. Results of this study will be shared with the WHO, published in scientific journals and presented at scientific meetings.
Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
DOIs
Publication statusAccepted for publication - 19 Dec 2020

Documents

  • INHALEd nebulised unfractionated HEParin

    Rights statement: The embargo end date of 2050 is a temporary measure until we know the publication date. Once we know the publication date the full text of this article will be able to view shortly afterwards.

    Accepted author manuscript (Post-print), 1.02 MB, PDF document

    Due to publisher’s copyright restrictions, this document is not freely available to download from this website until: 1/01/50

Related information

Relations Get citation (various referencing formats)

ID: 25506499